OBJECTIVE: To describe the viroimmunologic response and its prognostic factors 6 months after initiating triple antiretroviral therapy in a cohort of HIV-1-infected patients. METHODS: Positive virologic response during follow-up (VL+) was defined as plasma HIV RNA level <500 copies/ml and positive immunologic response (CD4+) as an increase of CD4+ count of at least 50 cells/mm3. Four categories of response were defined: VL+/CD4+; VL+/CD4-; VL-/CD4+ and VL-/CD4-. Prognostic factors were studied through a polytomous logistic regression (VL-/CD4-, as reference). RESULTS: Baseline characteristics of the 478 studied patients were: 22% at AIDS stage, 77% pretreated, median CD4+ cell count 195/mm3 and HIV RNA level 4.42 log. At 6 months 37.5% were VL+/CD4+; 15.7% VL+/CD4-; 23.8% VL-/CD4+ and 23.0% VL-/CD4-. Baseline HIV RNA level was associated to a higher risk of VL-/CD4+ response. More advanced age was associated with a higher risk of isolated immunologic failure (VL+/CD4-), whereas pretreatment and saquinavir therapy were associated with a lower frequency of positive virologic response independently of immunologic response. CONCLUSION: HIV-RNA level, pretreatment, and saquinavir therapy were already known to be linked to therapeutic response. Based on our results, a high baseline HIV-RNA level is associated with isolated immunologic response; moreover, age should be of importance in treatment decision.
OBJECTIVE: To describe the viroimmunologic response and its prognostic factors 6 months after initiating triple antiretroviral therapy in a cohort of HIV-1-infectedpatients. METHODS: Positive virologic response during follow-up (VL+) was defined as plasma HIV RNA level <500 copies/ml and positive immunologic response (CD4+) as an increase of CD4+ count of at least 50 cells/mm3. Four categories of response were defined: VL+/CD4+; VL+/CD4-; VL-/CD4+ and VL-/CD4-. Prognostic factors were studied through a polytomous logistic regression (VL-/CD4-, as reference). RESULTS: Baseline characteristics of the 478 studied patients were: 22% at AIDS stage, 77% pretreated, median CD4+ cell count 195/mm3 and HIV RNA level 4.42 log. At 6 months 37.5% were VL+/CD4+; 15.7% VL+/CD4-; 23.8% VL-/CD4+ and 23.0% VL-/CD4-. Baseline HIV RNA level was associated to a higher risk of VL-/CD4+ response. More advanced age was associated with a higher risk of isolated immunologic failure (VL+/CD4-), whereas pretreatment and saquinavir therapy were associated with a lower frequency of positive virologic response independently of immunologic response. CONCLUSION: HIV-RNA level, pretreatment, and saquinavir therapy were already known to be linked to therapeutic response. Based on our results, a high baseline HIV-RNA level is associated with isolated immunologic response; moreover, age should be of importance in treatment decision.
Authors: Eric Balestre; Serge P Eholié; Amani Lokossue; Papa Salif Sow; Man Charurat; Albert Minga; Joseph Drabo; François Dabis; Didier K Ekouevi; Rodolphe Thiébaut Journal: AIDS Date: 2012-05-15 Impact factor: 4.177
Authors: David M Moore; Ross Harris; Viviane Lima; Bob Hogg; Margaret May; Benita Yip; Amy Justice; Amanda Mocroft; Peter Reiss; Fiona Lampe; Geneviève Chêne; Dominique Costagliola; Luigia Elzi; Michael J Mugavero; Antonella D'Arminio Monforte; Caroline Sabin; Daniel Podzamczer; Gerd Fätkenheuer; Schlomo Staszewski; John Gill; Jonathan A C Sterne Journal: J Acquir Immune Defic Syndr Date: 2009-11-01 Impact factor: 3.731
Authors: Félix Gutierrez; Sergio Padilla; Mar Masiá; José A Iribarren; Santiago Moreno; Pompeyo Viciana; Leopoldo Muñoz; José L Gómez Sirvent; Francesc Vidal; José López-Aldeguer; José R Blanco; Manuel Leal; María Angeles Rodríguez-Arenas; Santiago Perez Hoyos Journal: PLoS One Date: 2006-12-20 Impact factor: 3.240
Authors: Giuseppe Lapadula; Liliane Chatenoud; Andrea Gori; Francesco Castelli; Simona Di Giambenedetto; Massimiliano Fabbiani; Franco Maggiolo; Emanuele Focà; Nicoletta Ladisa; Laura Sighinolfi; Massimo Di Pietro; Angelo Pan; Carlo Torti Journal: PLoS One Date: 2015-05-28 Impact factor: 3.240